Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
Clinical Drug Investigation · 2026
DOI: 10.1007/s40261-026-01533-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Drug Investigation, 2026. Verfasst von Michela Starace und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti 1, 40138, Bologna, Italy. Hauptthemen laut MEDLINE: Sulfonamides, Alopecia Areata, Azetidines, Nail Diseases. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss, which may extend to total scalp (AA totalis) or whole-body hair loss (AA universalis). Nail involvement, though often underestimated, occurs in up to 66% of cases, especially in severe forms and in children. OBJECTIVE: This retrospective study evaluated the efficacy of baricitinib 4 mg/day, a Janus kinase 1/2 inhibitor, in treating nail manifestations associated with severe AA. METHODS: Thirty-seven patients with very severe AA (Severity of Alopecia Tool [SALT] score > 50) and nail involvement were treated with baricitinib for 48 weeks. Nail changes assessed included trachyonichia, pitting, leukonychia, and others. Clinical assessments were performed at baseline and at 12, 24, 36, and 48 weeks using the SALT score, onychoscopy, and the Clinician Reported Outcome (ClinRO) for nail appearance. RESULTS: A significant improvement in both hair regrowth and nail abnormalities has been shown. The mean SALT score decreased from 100 to 16.3, and the average number of affected nails reduced from 6.4 to 2.1 (p < 0.001). ClinRO scores also significantly improved (p < 0.001). However, the correlation between hair and nail improvement was weak and not statistically significant (r = 0.15, p = 0.6). This suggests differential responsiveness of hair and nail units. CONCLUSIONS: The findings support baricitinib as a promising treatment for nail involvement in AA, highlighting the need for routine nail assessment and development of more refined evaluation tools. Limitations include small sample size and lack of long-term data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti 1, 40138, Bologna, Italy.
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti 1, 40138, Bologna, Italy. francesca.pampaloni@gmail.com.
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. francesca.pampaloni@gmail.com.
- Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
- Private Dermatology Practice, Bologna, Italy.
Zitieren
APA
Starace, M., Pampaloni, F., Quadrelli, F., Olivoni, G., Cedirian, S., Rapparini, L., Bruni, F., & Piraccini, B. M. (2026). Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study. Clinical Drug Investigation. https://doi.org/10.1007/s40261-026-01533-3
Vancouver
Starace M, Pampaloni F, Quadrelli F, Olivoni G, Cedirian S, Rapparini L, et al. Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study. Clinical Drug Investigation. 2026. doi:10.1007/s40261-026-01533-3
BibTeX
@article{Starace2026,
author = {Starace, Michela and Pampaloni, Francesca and Quadrelli, Federico and Olivoni, Giulia and Cedirian, Stephano and Rapparini, Luca and Bruni, Francesca and Piraccini, Bianca Maria},
title = {Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study},
journal = {Clinical Drug Investigation},
year = {2026},
doi = {10.1007/s40261-026-01533-3}
}
EUVIMED